Related Experiment Video
Updated: Aug 8, 2026
08:26
Design of a Biocompatible Drug-Eluting Tracheal Stent in Mice with Laryngotracheal Stenosis
Published on: January 21, 2020
Halofuginone prevents subglottic stenosis in a canine model
Ron Eliashar1, Meir Ochana, Bella Maly
1Department of Otolaryngology-Head and Neck Surgery, The Hebrew University School of Medicine, Hadassah Medical Center, Jerusalem, Israel.
The Annals of Otology, Rhinology, and Laryngology
|June 3, 2006
Summary
Halofuginone effectively prevents subglottic stenosis (SGS) in dogs by inhibiting fibrotic tissue formation. This study suggests halofuginone
Area of Science:
- Pharmacology and Toxicology
- Regenerative Medicine
- Otolaryngology
Background:
- Subglottic stenosis (SGS) is a serious airway complication.
- Current treatments for SGS have limitations.
- Halofuginone inhibits collagen synthesis and angiogenesis, suggesting potential anti-fibrotic properties.
Purpose of the Study:
- To evaluate the efficacy of halofuginone in preventing subglottic stenosis (SGS).
- To assess halofuginone's anti-fibrotic effects in a canine model of SGS.
Main Methods:
- Subglottic stenosis was surgically induced in 10 dogs.
- Dogs were randomly assigned to receive oral halofuginone (40 microg/kg) or placebo.
- Treatment was administered from 3 days before to 21 days after induction; subglottic lumen area was measured at 3 months; human tracheal fibroblasts were used for in vitro studies.
Main Results:
- No SGS was observed in halofuginone-treated dogs after 3 months, compared to 66%-80% stenosis in controls (p < .008).
- Halofuginone-treated larynges showed near-normal architecture, while placebo-treated larynges had significant fibrotic tissue.
- Halofuginone inhibited human tracheal fibroblast growth by 75%, comparable to mitomycin (60% inhibition).
Conclusions:
- Halofuginone demonstrated significant efficacy in preventing acute SGS in a canine model.
- The drug's anti-fibrotic action on fibroblasts supports its potential therapeutic role.
- Halofuginone shows promise for preventing SGS in human patients.
